drugset / Trial / NCT04061746
Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells
Phase 1
Active not recruiting
60 enrolled
Medical University of South Carolina
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this study is to determine the safety and efficacy of fresh metabolically active allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for the treatment of new-onset type 1 diabetes (T1D) and to understand the mechanisms of protection. If proven effective, such a strategy can be used as a therapeutic option for T1D patients and potentially other autoimmune disorders.
Timeline
- Start
- 2020-02-27
- Primary completion
- 2027-05-30
- Completion
- 2027-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mesenchymal stem cells | Cell therapy | 2.5e+06 cells/kg | Intravenous |